Biomakers, Inc.

Based in the US, and founded in 2014 by Nicolás Kirchuk, and Rubén Salanova, Biomakers, Inc. provides personalized cancer treatment by defining medical interventions based on genomic alterations found in patients' tumours. By using pathology and molecular biology tools, Biomakers analyze genomic biomarkers in tumour biopsies or liquid biopsies to guide targeted therapies. In January 2026, Biomakers, Inc.

raised USD 8 million in series A funding from LabCorp Ventures, Oncology Ventures, Endurance28, Zentynel Frontier Investments, Sonen Capital, and Sky High. Biomakers offer a genomic information production platform for genomic testing services, ensuring quick access to the best treatments available. The company uses various techniques such as immunohistochemistry, fluorescence in situ hybridization (FISH), real-time PCR, digital PCR, and next-generation sequencing (NGS) for testing. By leveraging advanced technology and artificial intelligence, tests analyze specific genetic alterations and protein expressions in tumour samples, providing valuable insights into the behaviour of the tumour and predicting its response to specific therapies.

The company offers a wide range of biomarker tests, such as tumour panel tests, including lung, colorectal, breast, sarcoma, and central nervous system panels, among others, that help diagnose and guide personalized treatment for various types of cancer.  Biomaker SA generates revenue from genomic and molecular diagnostic testing, precision oncology services, biomarker analysis, bioinformatics platforms, and data‑driven research collaborations. The company plans to use the January 2026 funding to to grow its precision oncology platform, integrate additional clinical data, and support its diagnostic and research operations.